Precision Oncology Pipeline

Novel targets from Portrai ATLAS, advanced into modality-fit therapeutic candidates

OVERVIEW

Discovery pipeline

Portrai's discovery pipeline starts with Portrai ATLAS, our proprietary spatial biology database. PortraiTARGET analyzes large-scale patient tissue data to discover novel therapeutic targets that are selectively expressed in tumors. Each POR Series target is selected not by expression alone, but by comprehensively evaluating its spatial distribution within the tumor, its selectivity against normal tissue, and its fit with therapeutic modalities. From these targets, Portrai develops modality-fit therapeutic candidates centered on ADC and RPT, expanding into diverse binder-based modalities such as multispecific antibodies, TCEs, and ISACs. Portrai does not stop at target discovery. It connects spatially defined targets to real therapeutic candidates.

PROGRAM	MODALITY	TARGET	DISCOVERY
POR001		CAF/TME Target
POR0011	ADC	ADC Candidate	Lead characterization
POR003		Tumor-selective Surface Target
POR0031	ADC	ADC Candidate	Binder discovery
POR006		Pan-SqCC Target
POR0061	ADC	ADC Candidate	Lead development
POR0063	RPT	Ab fragment-RPT Candidate	Binder discovery

PROGRAMS

Targets & asset candidates

POR001

CAF/TME Target

Target

POR001 is a Portrai ATLAS-derived novel TME target selectively expressed in CAF-rich tumor stroma. Its expression in normal tissue is limited, and it shows a more tumor-selective spatial expression pattern than conventional stromal targets.

Asset Candidate

POR0011ADC Candidate

POR0011 is a fully human IgG-based ADC candidate directed against POR001. Built on low-nanomolar binding affinity, high target specificity, and strong internalization, it is being developed as an ADC that selectively targets CAF-rich tumor stroma.

Lead characterization

Development Status: Lead characterization

Novel TME target discovered from Portrai ATLAS
Fully human IgG lead secured
Binding affinity, specificity, and internalization confirmed
ADC applicability under evaluation across diverse solid tumors

POR003

Tumor-selective Surface Target

Target

POR003 is a Portrai ATLAS-derived novel cell-surface target that shows tumor-selective expression across diverse solid tumors while remaining relatively limited in normal tissue. Promising expression has been observed in particular in CRC and PDAC, and it is being evaluated as a target that extends beyond any single indication to a broad range of solid tumors.

Asset Candidate

POR0031ADC Candidate

POR0031 is an ADC program directed against POR003, discovering binders that can exploit its differentiated tumor-to-normal expression profile. Its development potential is being evaluated across diverse solid tumors including CRC and PDAC.

Binder discovery

Development Status: Binder discovery

Novel cell-surface target from Portrai ATLAS
Tumor-selective expression across diverse solid tumors
Limited normal-tissue expression profile
Particularly promising expression in CRC and PDAC
Binder discovery underway for ADC development

POR006

Pan-SqCC Target

Target

POR006 is a Portrai ATLAS-derived novel Pan-SqCC cell-surface target. It shows broad patient coverage across diverse SqCC while remaining limited in normal tissue, and its accessible cell-surface expression enables expansion into multiple therapeutic modalities such as ADC and RPT.

Asset Candidates

POR0061ADC Candidate

POR0061 is a fully human IgG-based ADC candidate directed against POR006. Built on sub-nanomolar binding affinity and POR006's broad Pan-SqCC expression, it is being developed as an ADC covering diverse squamous cell carcinomas.

Lead development

POR0063Ab fragment-RPT Candidate

POR0063 is an antibody fragment-based RPT program directed against POR006. It is exploring RPT antibody-fragment candidates that can leverage POR006's Pan-SqCC expression.

Binder discovery

Development Status

Novel Pan-SqCC target from Portrai ATLAS
Broad tumor coverage confirmed across diverse SqCC
Fully human IgG lead secured for ADC
RPT antibody-fragment hit screening underway
Parallel ADC / RPT development strategy

PARTNERSHIP

Looking for development partners

Portrai discovers novel therapeutic targets grounded in spatial biology and AI, then expands each into therapeutic programs suited to its biology. We are seeking co-discovery, co-development, and licensing partnerships to accelerate the POR Series.

Co-Discovery

Co-discover novel targets optimized for a partner's modality using Portrai's spatial biology platform.

Asset Licensing

Licensing and co-development opportunities matched to each development stage, from target program to therapeutic asset.

Modality Expansion

Expand into diverse therapeutic modalities such as ADC, RPT, TCE, and multispecific antibodies, guided by each target's biology.

LET'S TALK

Ready to accelerate your oncology pipeline?

Connect with our Business Development team to discuss licensing opportunities, view confidential data rooms, or explore co-discovery partnerships.

Contact BD Team